Your session is about to expire
← Back to Search
Escitalopram + Brexpiprazole for Depression (CAN-BIND-17 Trial)
CAN-BIND-17 Trial Summary
This trial will test a predictive biomarker algorithm to help predict treatment outcome for patients with major depressive episodes. The algorithm uses data from previous studies on clinical features, imaging, EEG, and molecular information.
CAN-BIND-17 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAN-BIND-17 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAN-BIND-17 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I began psychological treatment in the last 3 months and plan to continue.I have tried 4 or more different depression medications without success.I am between 18 and 60 years old.I had issues with escitalopram or brexpiprazole, or antidepressants caused me to become overly energetic.I am between 18 and 60 years old.I have been diagnosed with Bipolar I or II.My main diagnosis is not major depressive disorder.I haven't taken any psychiatric medication for the required time before my first visit.I don't have significant mental health issues or conditions like arthritis.You have been diagnosed with a significant personality disorder, such as borderline or antisocial personality disorder.You have struggled with drug or alcohol addiction in the last 6 months.I have been diagnosed with major depression.My condition has lasted for 3 months or more.You have a high score on the MADRS scale, which measures symptoms of depression.I do not have any major neurological disorders or recent severe head injuries.The clinician thinks you may be at risk for harming yourself.
- Group 1: Random Allocation; Escitalopram + Brexpiprazole
- Group 2: Allocation by Predictive Biomarker Algorithm; Placebo
- Group 3: Random Allocation; Placebo
- Group 4: Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What type of disorder is the Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole treatment typically used to address?
"Major Depressive Disorder (MDD) is usually treated with a combination of Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole. This medication can also be effective at managing anxiety disorders, obsessive-compulsive disorder, and other antidepressive agents."
Are participants being actively sought for this research?
"At this moment, the clinical trial is not open to applicants. Its initial posting was on September 1st 2021 and it has been revised most recently on September 3rd 2021. Other studies are available for those with psychosis, involutional depression or Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole - 1295 trials in total that seek participants."
Is geriatric enrollment a priority in this medical research?
"For this particular trial, participants must be of legal age and not older than 60. Meanwhile, 196 studies are available for those younger than 18 years old, while 988 trials cater to seniors."
How has the efficacy of Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole been evaluated in previous investigations?
"Currently, 31 clinical trials are underway that explore the efficacy of Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole. Of these ongoing studies, 11 have reached Phase 3 while being conducted at 59 distinct sites across New york City."
May I be eligible to join this medical study?
"Participants of this trial must be 18-60 years old, have involutional psychosis, and a MADRS score greater than 24. Additionally, they should not have taken psychotropic medications in the past 5 half lives prior to enrollment. This study is seeking 400 outpatients for its research project."
Has the FDA sanctioned Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole?
"The risk profile of Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole has been assessed as a 3, given that this is a Phase 4 trial and the intervention has already received regulatory approval."
Are there many health care facilities administering this trial in North America?
"Currently, this experiment is running at 6 different sites: Hamilton, Kingston and Toronto are included in the list. To lessen travel time for potential participants it would be wise to choose a site located close proximity."
How many volunteers are taking part in this experiment?
"The recruitment period for this medical trial has already elapsed, having first been posted on September 1st 2021 and last edited on the 3rd. However, there are presently 1295 clinical trials searching for participants with psychosis as well as 31 studies actively enrolling patients using an Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole protocol."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger